/MNMD
MNMD Stock - Mind Medicine (MindMed) Inc.
Healthcare|BiotechnologyNASDAQ
$12.70+1.28%
+$0.16 (+1.28%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.88
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.8
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+120.5%upside
Target: $28.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MNMD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$12.57 – $12.83
TARGET (TP)$28.00
STOP LOSS$11.68
RISK/REWARD1:15.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.80
52W High$14.43
52W Low$4.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-527,000 | $-3,162,000 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-103,916,000 | $-93,866,000 | $-66,331,000 | $-93,854,000 | $-33,030,000 |
| Net Income | $-108,679,000 | $-95,732,000 | $-56,796,000 | $-93,036,000 | $-34,101,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.54 | $-2.44 | $-1.53 | $-3.40 | $-1.92 |
Company Overview
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
13
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
13 Bullish0 Neutral/Bearish
Price Targets
$18
Average Target
↑ 41.5% Upside
Now
$3
Low
$18
Average
$36
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 13th 2025 | Needham | Initiation | Buy | $28 |
| August 4th 2025 | Oppenheimer | Resumed | Outperform | $25 |
| January 28th 2025 | Evercore ISI | Initiation | Outperform | $23 |
| December 20th 2024 | Chardan Capital Markets | Initiation | Buy | $20 |
| October 14th 2024 | Leerink Partners | Resumed | Outperform | $20 |
| July 24th 2024 | ROTH MKM | Initiation | Buy | $36 |
| May 29th 2024 | Robert W. Baird | Initiation | Outperform | $27 |
| April 15th 2024 | Leerink Partners | Initiation | Outperform | $20 |
| December 5th 2023 | Canaccord Genuity | Initiation | Buy | $9 |
| December 9th 2022 | ROTH Capital | Resumed | Buy | $25 |
| November 16th 2022 | RBC Capital Mkts | Initiation | Outperform | $5 |
| August 26th 2022 | Oppenheimer | Initiation | Outperform | $3.5 |
| August 10th 2022 | Cantor Fitzgerald | Initiation | Overweight | $3 |
| May 4th 2022 | ROTH Capital | Initiation | Buy | $7 |
Earnings History & Surprises
MNMDBeat Rate
44%
Last 18 quarters
Avg Surprise
-18.1%
EPS vs Estimate
Beats / Misses
8/10
Last 12 quarters
Latest EPS
$-0.78
Q4 2025
EPS Surprise History
Q1 24
-22.9%
$-0.59vs$-0.48
Q2 24
+9.1%
$-0.60vs$-0.66
Q3 24
-60.0%
$-0.48vs$-0.30
Q4 24
+6.9%
$-0.27vs$-0.29
Q1 25
-24.2%
$-0.41vs$-0.33
Q2 25
+2.8%
$-0.35vs$-0.36
Q3 25
-31.6%
$-0.50vs$-0.38
Q4 25
-50.0%
$-0.78vs$-0.52
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 5, 2026 | $-0.48 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.52 | $-0.78 | -50.0% | ✗ MISS |
Q3 2025 | Jul 31, 2025 | $-0.38 | $-0.50 | -31.6% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.36 | $-0.35 | +2.8% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.33 | $-0.41 | -24.2% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.29 | $-0.27 | +6.9% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.30 | $-0.48 | -60.0% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.66 | $-0.60 | +9.1% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.48 | $-0.59 | -22.9% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.65 | $-0.53 | +18.5% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.54 | $-0.72 | -33.3% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.41 | $-0.51 | -24.4% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-0.49 | $-0.27 | +44.9% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.58 | $-0.56 | +3.4% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.75 | $-0.60 | +20.0% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.75 | $-0.60 | +20.0% | ✓ BEAT |
Q1 2022 | Mar 28, 2022 | $-0.70 | $-0.75 | -7.1% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.52 | $-0.90 | -73.1% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.60 | $-1.35 | -125.0% | ✗ MISS |
Q2 2021 | May 14, 2021 | — | $-0.57 | — | — |
Latest News
Canaccord Genuity Maintains Buy on Mind Medicine, Raises Price Target to $25
📈 PositiveBenzinga•Nov 7, 2025, 09:51 PM•Also:
RBC Capital Maintains Outperform on Mind Medicine, Lowers Price Target to $20
➖ NeutralBenzinga•Nov 7, 2025, 07:13 PM
Mind Medicine Q3 EPS $(0.78) Misses $(0.50) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 09:04 PM
Reported Earlier, MindMed Prices $225M Public Offering Of 18.375M Shares At $12.25 Each To Fund R&D And Corporate Growth
➖ NeutralBenzinga•Oct 30, 2025, 08:10 AM
Mind Medicine announces proposed public offering
➖ NeutralSeeking Alpha•Oct 29, 2025, 08:10 PM
Mind Medicine Announces Proposed Public Offering; Amount Not Disclosed
➖ NeutralBenzinga•Oct 29, 2025, 08:02 PM
Psychedelic stocks gain after positive remarks from GOP Senator in North Carolina
📈 PositiveSeeking Alpha•Oct 14, 2025, 06:06 PM•Also: , ,
'Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment,' Research Suggests' - Marijuana Moment
📈 PositiveBenzinga•Oct 13, 2025, 05:28 PM•Also: , ,
Needham Initiates Coverage On Mind Medicine with Buy Rating, Announces Price Target of $28
📈 PositiveBenzinga•Oct 13, 2025, 10:06 AM
'New York Lawmakers Hold Hearing Psilocybin's Medical Benefits Amid Broader Debate Over Psychedelics Reform' - Marijuana Moment
➖ NeutralBenzinga•Oct 2, 2025, 03:03 PM•Also: , ,
MindMed Study Finds Nearly Half Of Adults With Severe Anxiety Report Suicidal Thoughts Almost Every Day
📉 NegativeBenzinga•Sep 19, 2025, 11:02 AM
'Massachusetts Lawmakers Approve Bill To Create Psychedelic Therapy Pilot Program' - Marijuana Moment
📈 PositiveBenzinga•Sep 12, 2025, 04:30 PM•Also: , ,
MindMed Publishes Phase 2b MM120 (LSD) Results In JAMA, Demonstrating Statistically Significant And Sustained Anxiety Reduction In GAD Patients; 100 µg Dose Achieved 65% Response, 48% Remission At Week 12, Supporting Ongoing Phase 3 Trials And FDA Breakthrough Therapy Designation
📈 PositiveBenzinga•Sep 4, 2025, 03:15 PM
'Military To Start Testing Service Members For The Psychedelic Psilocin, Memo Shows' - Marijuana Moment
➖ NeutralBenzinga•Aug 28, 2025, 06:16 PM•Also: , ,
'GOP Senator Is 'Confident' Psychedelics Access Will Expand Under Trump, Saying Many Veterans Speak To Him About The Benefits' - Marijuana Moment
📈 PositiveBenzinga•Aug 22, 2025, 07:53 PM•Also: , ,
'U.S. Senate Committee To Hold Hearing On Benefits Of Psychedelics For Military Veterans'- Marijuana Moment
📈 PositiveBenzinga•Aug 21, 2025, 06:35 PM•Also: , ,
MindMed Reports Strong Q2 2025 Results
📈 PositiveThe Motley Fool•Aug 11, 2025, 08:37 AM
Mind Medicine upgraded at Oppenheimer on lead asset
📈 PositiveSeeking Alpha•Aug 4, 2025, 06:38 PM
Frequently Asked Questions about MNMD
What is MNMD's current stock price?
Mind Medicine (MindMed) Inc. (MNMD) is currently trading at $12.70 per share. The stock has moved +1.28% today.
What is the analyst price target for MNMD?
The average analyst price target for MNMD is $28.00, based on 1 analyst.
What sector is Mind Medicine (MindMed) Inc. in?
Mind Medicine (MindMed) Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MNMD's market cap?
Mind Medicine (MindMed) Inc. has a market capitalization of $0.96 billion, making it a small-cap company.
Does MNMD pay dividends?
No, Mind Medicine (MindMed) Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANAB
AnaptysBio, Inc.
$49.08
Mkt Cap: $1.4B
BBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
FTRE
Fortrea Holdings Inc.
$17.74
Mkt Cap: $1.6B
KOD
Kodiak Sciences Inc.
$26.00
Mkt Cap: $1.4B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
SVRA
Savara Inc.
$6.05
Mkt Cap: $1.2B
TNGX
Tango Therapeutics, Inc.
$8.52
Mkt Cap: $0.9B
URGN
UroGen Pharma Ltd.
$22.80
Mkt Cap: $1.1B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to MNMD for comparison